3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
25
Neoplasms
14
Colorectal Neoplasms
14
Melanoma
12
Carcinoma, Renal Cell
11
Neoplasm Metastasis
9
Solid Tumors
8
Carcinoma, Hepatocellular
8
Head and Neck Neoplasms
7
Urinary Bladder Neoplasms
6
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Ovarian Neoplasms
6
Lung Neoplasms
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Uterine Cervical Neoplasms
5
Lymphoma
5
Kidney Neoplasms
4
Endometrial Neoplasms
4
Solid Tumor
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Advanced Solid Tumors
3
Urologic Neoplasms
2
Treatment-Refractory Solid Tumors
2
Solid Cancers
2
Recurrence
2
Interventions
Oxaliplatin
31
Fluorouracil
31
Leucovorin
29
Irinotecan
23
Cetuximab
20
Bevacizumab
16
Capecitabine
13
Gemcitabine
11
pembrolizumab
8
Folfox protocol
7
Cisplatin
7
Carboplatin
7
Paclitaxel
6
Nivolumab
6
Cyclophosphamide
6
trifluridine tipiracil drug combination
5
cediranib
5
Erlotinib Hydrochloride
5
adagrasib
4
Ipilimumab
4
IFL protocol
4
Floxuridine
4
Bortezomib
4
veliparib
3
trametinib
3
sargramostim
3
poly ICLC
3
binimetinib
3
Trifluridine
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Colonic Neoplasms
×
atezolizumab
×
Clear all
NCT04108481
2025-03-28
iRE-C
University of Iowa
Phase 1
Terminated
5 enrolled